Cover Image

Cover Image

Human mast cells cultured from peripheral blood in the presence of stem cell factor, cytoprepped, stained with toluodine blue, and visualized at 400× magnification. See the related article by Metcalfe beginning on page 946.
Front Matter
Table of Contents
Back Matter
Advertising
Editorial Board

Issue Archive

Table of Contents

INSIDE BLOOD

ASH 50TH ANNIVERSARY REVIEW

PLENARY PAPERS

REVIEW IN TRANSLATIONAL HEMATOLOGY

CLINICAL TRIALS AND OBSERVATIONS

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia Clinical Trials & Observations

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia Clinical Trials & Observations

Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction Clinical Trials & Observations

Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study Clinical Trials & Observations

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia Clinical Trials & Observations

Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement Clinical Trials & Observations

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose Clinical Trials & Observations

High expression of CD40 on B-cell precursor acute lymphoblastic leukemia blasts is an independent risk factor associated with improved survival and enhanced capacity to up-regulate the death receptor CD95 Clinical Trials & Observations

First thalidomide clinical trial in multiple myeloma: a decade Brief Report

EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma Brief Report

HEMATOPOIESIS AND STEM CELLS

HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY

Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell–depleting therapy with rituximab Brief Report

Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors Brief Report

Angiopoietin-1 mediates the proangiogenic activity of the bone morphogenic protein antagonist Drm Brief Report

IMMUNOBIOLOGY

Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura Brief Report

NEOPLASIA

PHAGOCYTES

RED CELLS

Impaired CD163-mediated hemoglobin-scavenging and severe toxic symptoms in patients treated with gemtuzumab ozogamicin Brief Report

TRANSPLANTATION

Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival Brief Report

CORRESPONDENCE

ERRATA

Cover Image

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
Clinical Trials & Observations

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia
Clinical Trials & Observations

Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction
Clinical Trials & Observations

Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study
Clinical Trials & Observations

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia
Clinical Trials & Observations

Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement
Clinical Trials & Observations

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose
Clinical Trials & Observations

High expression of CD40 on B-cell precursor acute lymphoblastic leukemia blasts is an independent risk factor associated with improved survival and enhanced capacity to up-regulate the death receptor CD95
Clinical Trials & Observations

First thalidomide clinical trial in multiple myeloma: a decade
Brief Report

EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma
Brief Report

Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell–depleting therapy with rituximab
Brief Report

Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors
Brief Report

Angiopoietin-1 mediates the proangiogenic activity of the bone morphogenic protein antagonist Drm
Brief Report

Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura
Brief Report

Impaired CD163-mediated hemoglobin-scavenging and severe toxic symptoms in patients treated with gemtuzumab ozogamicin
Brief Report

Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival
Brief Report